Shannon’s “upside for the near term is the old highs from $265 to $270. That gives a potential $35 of profits per share, assuming a $235 entry point,” according to Yahoo.
The $5 billion IBB ranked among the 10 best non-leveraged sector ETFs in three consecutive years ending 2013.
iShares Nasdaq Biotechnology ETF
ETF Trends editorial team contributed to this post.